# US 2019/0292132 A1 · Compounds and methods for hematopoietic regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292132 A1
- Document ID: US20190292132A1
- Status: Published application
- Kind: A1
- Application number: 16/304,427
- Filed: 2017-05-26
- Published: 2019-09-26
- Earliest claimed: 2016-05-26
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: John P. Chute; Michael E. Jung; Emelyne Diers
- Web page: https://patentgrep.com/patent/US20190292132A1

## CPC

- C07C 225/16: and containing six-membered aromatic rings
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 205/37: the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- C07C 225/22: having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 233/31: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C 311/39: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C 311/44: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 211/58: attached in position 4
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 295/205: Radicals derived from carbonic acid
- C07D 307/46: Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 317/66: Nitrogen atoms not forming part of a nitro radical
- C07D 333/22: Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07C 2601/02: with a three-membered ring
- C07C 2601/14: The ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.

## Claims

### Claim 1

A compound having the structure of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:
wherein:
A is selected from alkyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
B is aryl or heteroaryl;
R4 and R5 are each independently selected from H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, and halo, or R4 and R5 together with the ethylene moiety that separates them may form a ring;
X is selected from 0, S, or NW;
Q is selected from 0, S, or NRa; and
each instance of Ra is selected from H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, silyloxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, nitro, halo and cyano, or, when X and Q are both NRa, two occurrences of Ra together represent a single bond between X and Q.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 3 (depends on 1)

A method of inhibiting PTPσ in a cell, comprising contacting the cell with a compound of claim 1.

### Claim 4 (depends on 1)

A method of promoting the self-renewal or regeneration of hematopoietic stem cells comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

### Claim 5 (depends on 1)

The compound of claim 1, wherein B is not 3,4-dichlorophenyl; and if A is phenyl and B is unsubstituted phenyl, then A is substituted with at least one substituent selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, halo and cyano.

### Claim 6 (depends on 1)

The compound of claim 1, wherein A is selected from alkyl, cycloalkyl, cycloalkenyl, or heterocyclyl.

### Claim 7 (depends on 5)

The compound of claim 5, wherein A is selected from methyl, ethyl, propyl, cyclopropyl, n-butyl, sec-butyl, tert-butyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, or piperazinyl.

### Claim 8 (depends on 5)

The compound of claim 5, wherein A is selected from aryl, aralkyl, heteroaryl, or heteroaralkyl.

### Claim 9 (depends on 5)

The compound of claim 5, wherein A is selected from phenyl, benzyl, furanylmethyl, naphthyl, or benzodioxole.

### Claim 10 (depends on 1)

The compound of claim 1, wherein A is substituted with at least one substituent selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, halo and cyano.

### Claim 11 (depends on 1)

The compound of claim 1, wherein B is selected from phenyl, furanyl, cyclohexyl, thiophene, or naphthyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R4 and R5 are each independently selected from H, alkyl, or cycloalkyl; or R4 and R5 together with the ethylene moiety that separates them form a phenylene ring.

### Claim at position 13

13-14. (canceled)

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound has the structure of formula (II) or a pharmaceutically acceptable salt or prodrug thereof:
wherein:
R1 and R2 are independently selected from H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, silyloxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, nitro, halo and cyano;
n is 0, 1, 2, 3, 4, or 5;
each instance of R3 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, nitro, halo and cyano; and
R4 and R5 are each independently selected from H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, and halo, or R4 and R5 together with the ethylene moiety that separates them may form a ring.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The compound of claim 15, composition, wherein the compound has the structure of formula (IIb) or (IIc), or a pharmaceutically acceptable salt or prodrug thereof:

### Claim 18 (depends on 15)

The compound of claim 15, R1 is selected from H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, nitro, halo and cyano; and R2 is selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, halo and cyano.

### Claim at position 18

19-21. (canceled)

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound has the structure of formula (III), formula (IIIa), or a pharmaceutically acceptable salt or prodrug thereof:
wherein:
R1 and R2 are independently selected from H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, silyloxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, nitro, halo and cyano;
n is 0, 1, 2, 3, 4, or 5;
each instance of R3 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, amino, sulfonyl, carbonyl, nitro, halo and cyano; and
R4 and R5 are each independently selected from H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, and halo, or R4 and R5 together with the ethylene moiety that separates them may form a ring.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 3)

The method of claim 3, wherein the subject is myelosuppressed.

### Claim 26 (depends on 3)

The method of claim 3, wherein the subject has received or is receiving myelosuppressive chemotherapy or radiotherapy, has undergone or is undergoing hematopoietic cell transplantation, or is suffering from with aplastic anemia or a degenerative hematologic disease.

### Claim at position 24

27-30. (canceled)
